MODIFICATION
A -- Destinations of Released Patients Following Treatment with Iodine-131, and Optionally Estimation of Doses to Staff at Nursing Homes Receiving Such Patients - Amendment 3
- Notice Date
- 12/24/2013
- Notice Type
- Modification/Amendment
- NAICS
- 541712
— Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
- Contracting Office
- Nuclear Regulatory Commission, Acquisition Management Division, Acquisition Management Division, 11555 Rockville Pike, Rockville, Maryland, 20852-2738, United States
- ZIP Code
- 20852-2738
- Solicitation Number
- NRC-HQ-13-R-04-0167
- Archive Date
- 1/25/2014
- Point of Contact
- La'toya Cooper, Phone: (301) 287-0886
- E-Mail Address
-
latoya.cooper@nrc.gov
(latoya.cooper@nrc.gov)
- Small Business Set-Aside
- Total Small Business
- Description
- Amendment No. 003 Radioactive iodine, mainly the isotope Iodine-131, is used in the diagnosis and treatment of several medical conditions, the primary ones in the present context being treatment of hyperthyroidism and thyroid cancer following thyroidectomy. The importance of these conditions arises from the fact that their treatment protocols generally call for administration of relatively large doses of Iodine-131, and such patients therefore pose the greatest potential for exposure of others. Patients are often released from the hospital following treatment if they meet the release conditions specified in the Nuclear Regulatory Commission's (NRC) Code of Federal Regulations (CFR) Title 10, Part 35.75, "Release of individuals containing unsealed byproduct material or implants containing byproduct material." The basic criterion underlying the release conditions is that "the total effective dose equivalent to any other individual from exposure to the released individual is not likely to exceed 5 mSv (0.5 rem)." To assist licensees in implementing the above release requirement, NRC published Regulatory Guide 8.39, "Release of patients administered radioactive materials." This guide provides formulas and tables that are considered acceptable to NRC in translating the basic 5 mSv requirement into operational quantities to be used in releasing patients. For example, an operational quantity used in releasing patients is the dose rate measured at a specified distance from the patient. The formulas and tables in the guide use very conservative assumptions in estimating the dose to an individual that results from exposure to the released patient, but the guide also permits licensees to base their calculations on patient-specific conditions, which are often much less conservative than the generic conditions. There have been a number of publications in the technical, peer-reviewed literature describing studies that attempted to measure or estimate the doses received by persons coming in contact with released patients, and a preliminary review of some of these publications suggested that the release condition of 5 mSv noted above is being met in practice. However, the NRC Commission has decided that a more extensive review of available data, and a re-examination of the calculation methods and tables described in Regulatory Guide 8.39, shall be conducted to ensure that exposures to members of the public resulting from release of patients according to 10 CFR 35.75 do in fact meet the release criterion, and that the methods used to calculate operational release criteria are reasonably accurate and not excessively conservative. In addition, the Commission instructed staff to generate additional data on exposure of members of the public if the available data is considered to be insufficient to provide reasonable assurance that the release criterion is being met in practice. The objective of tasks under this upcoming solicitation are to undertake, through contracts, to carry out the Commission's directions. To supplement data found in the available literature on typical exposures to members of the public that are expected to come in proximity of released patients who were treated with high activities of Iodine-131 for hyperthyroidism and thyroid cancer. Exposed persons include personnel at the hotels and nursing homes where patients sometimes stay immediately following their release from the hospital. Measurements made under this task, however, shall only include nursing home and hotel staff. The study shall include collection of data on both external and internal doses, and may involve measurement of doses using personnel dosimetry for external exposures and some form of bioassay for internal exposures. The resulting contract is expected to be a cost-plus-fixed fee contract. The expected period of performance is 16 months, with an option to extend to 24 months. This procurement is expected to be awarded in Fiscal Year 2014.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/NRC/OA/DCPM/NRC-HQ-13-R-04-0167/listing.html)
- Place of Performance
- Address: Contractors place of business, United States
- Record
- SN03258022-W 20131226/131224233906-324c61a9261267a75841057683775729 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |